Revenio Group Oyj, a health technology company, designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration in Finland, Italy, rest of Europe, the United States, and internationally.
No risks detected for REG1V from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||€58.15|
|52 Week High||€33.50|
|52 Week Low||€72.00|
|1 Month Change||-6.44%|
|3 Month Change||-5.06%|
|1 Year Change||53.23%|
|3 Year Change||272.76%|
|5 Year Change||520.82%|
|Change since IPO||2,960.60%|
Recent News & Updates
Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
The Returns On Capital At Revenio Group Oyj (HEL:REG1V) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
If You Like EPS Growth Then Check Out Revenio Group Oyj (HEL:REG1V) Before It's Too Late
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|REG1V||FI Medical Equipment||FI Market|
Return vs Industry: REG1V exceeded the Finnish Medical Equipment industry which returned 41.1% over the past year.
Return vs Market: REG1V exceeded the Finnish Market which returned 24.4% over the past year.
Stable Share Price: REG1V is not significantly more volatile than the rest of Finnish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: REG1V's weekly volatility (5%) has been stable over the past year.
About the Company
Revenio Group Oyj, a health technology company, designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration in Finland, Italy, rest of Europe, the United States, and internationally. The company offers ic100 and ic200 tonometers; Icare HOME, a device for self-measurement of eye pressure; Icare TONOVET Plus tonometers for animals; fundus imaging devices comprising EIDON, DRS, and DRSplus; MAIA, a microperimeter to measure the effectiveness of drugs for retinal disease treatment; COMPASS, which provides fundus perimetry with true-color confocal retinal images; and Ventica, to examine the variability in tidal breathing in children. It is also developing Cutica, a hyperspectral camera for dermatologists to detect skin cancers.
Revenio Group Oyj Fundamentals Summary
|REG1V fundamental statistics|
Is REG1V overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|REG1V income statement (TTM)|
|Cost of Revenue||€21.03m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 21, 2021
|Earnings per share (EPS)||0.60|
|Net Profit Margin||22.52%|
How did REG1V perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Revenio Group Oyj undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: REG1V (€58.15) is trading below our estimate of fair value (€62.91)
Significantly Below Fair Value: REG1V is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: REG1V is poor value based on its PE Ratio (96.2x) compared to the European Medical Equipment industry average (39.4x).
PE vs Market: REG1V is poor value based on its PE Ratio (96.2x) compared to the Finnish market (23.5x).
Price to Earnings Growth Ratio
PEG Ratio: REG1V is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: REG1V is overvalued based on its PB Ratio (22.9x) compared to the XE Medical Equipment industry average (4.9x).
How is Revenio Group Oyj forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REG1V's forecast earnings growth (22.2% per year) is above the savings rate (0.2%).
Earnings vs Market: REG1V's earnings (22.2% per year) are forecast to grow faster than the Finnish market (7.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: REG1V's revenue (15.9% per year) is forecast to grow faster than the Finnish market (3.7% per year).
High Growth Revenue: REG1V's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: REG1V's Return on Equity is forecast to be high in 3 years time (25.8%)
How has Revenio Group Oyj performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REG1V has high quality earnings.
Growing Profit Margin: REG1V's current net profit margins (22.5%) are higher than last year (20.5%).
Past Earnings Growth Analysis
Earnings Trend: REG1V's earnings have grown significantly by 20.8% per year over the past 5 years.
Accelerating Growth: REG1V's earnings growth over the past year (42.9%) exceeds its 5-year average (20.8% per year).
Earnings vs Industry: REG1V earnings growth over the past year (42.9%) underperformed the Medical Equipment industry 59.7%.
Return on Equity
High ROE: REG1V's Return on Equity (23.8%) is considered high.
How is Revenio Group Oyj's financial position?
Financial Position Analysis
Short Term Liabilities: REG1V's short term assets (€27.7M) exceed its short term liabilities (€14.9M).
Long Term Liabilities: REG1V's short term assets (€27.7M) exceed its long term liabilities (€26.7M).
Debt to Equity History and Analysis
Debt Level: REG1V's debt to equity ratio (38.5%) is considered satisfactory.
Reducing Debt: REG1V's debt to equity ratio has increased from 5.6% to 38.5% over the past 5 years.
Debt Coverage: REG1V's debt is well covered by operating cash flow (66.7%).
Interest Coverage: REG1V's interest payments on its debt are well covered by EBIT (157.8x coverage).
What is Revenio Group Oyj current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: REG1V's dividend (0.55%) isn’t notable compared to the bottom 25% of dividend payers in the Finnish market (1.68%).
High Dividend: REG1V's dividend (0.55%) is low compared to the top 25% of dividend payers in the Finnish market (3.64%).
Stability and Growth of Payments
Stable Dividend: REG1V is not paying a notable dividend for the Finnish market, therefore no need to check if payments are stable.
Growing Dividend: REG1V is not paying a notable dividend for the Finnish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: REG1V is not paying a notable dividend for the Finnish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of REG1V's dividend in 3 years as they are not forecast to pay a notable one for the Finnish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jouni Toijala (53 yo)
Mr. Jouni Toijala serves as Chief Executive Officer of Revenio Group Oyj. He served as Chief Executive Officer of Innokas Medical Oy. He served as Managing Director of EMEA at Symbio, Inc. Mr. Toijala join...
CEO Compensation Analysis
Compensation vs Market: Jouni's total compensation ($USD250.01K) is below average for companies of similar size in the Finnish market ($USD853.06K).
Compensation vs Earnings: Insufficient data to compare Jouni's compensation with company performance.
Experienced Management: REG1V's management team is considered experienced (3.8 years average tenure).
Experienced Board: REG1V's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Revenio Group Oyj's employee growth, exchange listings and data sources
- Name: Revenio Group Oyj
- Ticker: REG1V
- Exchange: HLSE
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €1.545b
- Shares outstanding: 26.56m
- Website: https://www.reveniogroup.fi
Number of Employees
- Revenio Group Oyj
- Aeyritie 22
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 21:38|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.